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The  mechanism  of the  pathogenesis  of rheumatic  fever  and  rheumatic  carditis 
remains  unknown  (1).  Efforts to vaccinate  against  group A  streptococci  have been 
hampered by toxicity of most preparations of M  protein and the fear that streptococcal 
vaccines  may  contain  some  of the  antigens  shown  to  be  cross-reactive  with  heart 
tissues  (2-4) and, therefore, theoretically may trigger, rather than prevent, rheumatic 
fever and carditis. 
It has been recognized for a long time that the resistance of group A streptococci to 
phagocytosis is largely attributable to the presence on the surface of virulent organisms 
of a  type-specific antigen,  the M  protein.  Hosts who are immune to a  particular  M 
serotype of streptococci possess antibodies  that render organisms bearing the homol- 
ogous type of M  protein on their surfaces susceptible to ingestion and killing by host 
phagocytes  (5).  Efforts to purify the M  antigen  in the past,  however, have failed to 
separate  heterologous  protein  antigens  from  the  type-specific  determinant  of M 
protein  (6-11).  Moreover,  after  extensive  purification,  the  M  antigen  often  became 
less  immunogenic  and  was  of questionable  value  in  affording protective  immunity 
(12). 
In our search  for more effective methods for the extraction and purification of M 
protein for use as vaccines, we found that the antigen could be extracted in satisfactory 
yields by subjecting  intact  streptococci  to limited  digestion  with  pepsin  (13).  Upon 
purification of the peptic extracts of types 6 and 24 M  protein (pep M) 1 by ammonium- 
sulfate  precipitation,  ion-exchange  chromatography,  and  isoelectric  focusing,  the 
heterologous, heart-reactive, and toxic materials were readily separated from the type- 
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specific  M  antigen  (14).  Physiochemical  analysis  and  partial  amino  acid  sequence 
analysis  indicated  that  these  fragments  of M  protein  molecules  are  composed of a 
single, unbranched polypeptide chain  (15). 
The  type  24  pep  M  protein  (pep  M24)  molecule  was  cleaved  with  cyanogen 
bromide into seven peptides, each of which, after purification, inhibited  type-specific 
opsonic antibody,  and  therefore,  each peptide  presumably contained  the protective 
determinant.  Partial sequence analyses of the seven peptides suggested that the type- 
specific antiopsonic  determinant  resides  in  a  repeating  amino  acid sequence  in  the 
intact M  protein molecule (16). When incorporated into complete Freund's adjuvant 
and  injected  into  laboratory  animals,  the  intact  pep  M24  evoked  type-specific 
protective antibodies. The immune sera were free of non-type-specific antibodies that 
are cross-reactive with M-associated antigens  (14,  15).  Furthermore,  they were free of 
cross-reactivity with human heart  tissue. 
Having established  that the purified pep M  protein was immunogenic and free of 
immunological cross-reactivity with heart tissue, we initiated  studies of the immuno- 
genicity of this unique antigenic molecule in man. In this paper, we describe the type- 
specific immunogenic properties of alum precipitates  of pep M24,  first in laboratory 
animals  and  then  in man.  Our data  indicate  that  immunization  with  the adjuvant 
mixture  induces  type-specific protective  immunity  in  laboratory  animals.  We show 
further  that  the  pep  M24  vaccine  is  well-tolerated  in  doses  sufficient  to  produce 
similarly type-specific, primary opsonic and protective antibody responses in man. 
Materials  and Methods 
Purification of Streptococcal MProtein.  M protein prepared from limited peptic digests of whole, 
group A streptococci was obtained in pure form as judged by sodium dodecyl sulfate  (SDS)- 
polyaerylamide gel electrophoresis, quantitative amino acid analysis, and Edman degradation, 
by methods previously described (14,  16). The streptococci were grown in Todd-Hewitt broth 
(Difco Laboratories, Detroit, Mich.) in 60-liter batches for 16 h, sedimented by centrifugation, 
washed twice in 20 mM phosphate/0.15 M NaCI, pH 7.4 (PBS), and once in 67 mM phosphate, 
pH  5.8.  The organisms were finally  resuspended  in  three  volumes of the buffer at  pH  5.8 
containing 50/~g of pepsin/ml (Worthington Biochemical Corp., Freehold, N. ,J.) and incubated 
for 1 h at 37°C. Digestion was stopped by adding 7.5% NaHCO3 to raise the pH to 7.5. After 
incubation  for  1 h  at  25°C,  the  organisms  were sedimented  by centrifugation  at  10,000 g 
(DuPont Instruments-Sorvall Operations, DuPont Co., Newtown, Conn.) for 20 min, and the 
cells were extracted a second time with pepsin under identical conditions. The supernates were 
combined,  filtered  through  a  0.45-p,m  membrane  filter  (Millipore  Corp.,  Bedford,  Mass.), 
dialyzed against PBS, lyophilized, redissolved in 10 ml distilled water, further dialyzed against 
distilled water, and relyophilized. The lyophilized material containing the M  protein antigens 
was redissolved in PBS and precipitated by slowly adding saturated  ammonium sulfate. The 
type 24  M  antigen  was precipitated  at  30%  saturation,  whereas  the type 6  M  antigen  was 
precipitated between 30 and 60% saturation with ammonium sulfate.  The ammonium sulfate 
precipitates were redissolved, digested with ribonuclease, dialyzed, lyophilized as described by 
Lancefield and Perlmann (17), and designated pep M. 
The partially purified pep M preparations were redissolved in 50 mM Tris-HCl buffer at pH 
7.5 and fractionated by ion-exchange chromatography on columns of quarternary aminoethyl 
Sephadex A-50 (Pharmacia Fine chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.)  (14). 
The material eluted at a salt concentration of 0.2 M  NaCI (18). It was homogeneous on SDS- 
gels  (19) and by quantitative amino acid analysis (20);  the final isoelectrofocusing step (14), 
therefore, was omitted. The elution peak containing the homogeneous pep M in each case was 
dialyzed against  distilled  water  and  lyophilized.  The purified  material  was assayed  for the 
presence of the type-specific anti-opsonic and  immunoprecipitating antigen  by the methods 
previously described in detail (14,  16). 864  IMMUNOGENICITY OF  M  PROTEIN  IN  MAN 
Preparation ofpep M Antigens for Injection.  For skin testing, the lyophilized pep M  preparations 
were dissolved at the appropriate concentrations in sterile water for injection (without preserv- 
atives).  Under sterile precautions,  the pep  M  solutions were sterilized by passing  through  a 
0.45-/~m  membrane  filter and  packaged  in  sterile  multiple-dose  vials  and  lyophilized. Just 
before use, the lyophilized antigens were dissolved in the appropriate  amount of sterile 0.85% 
NaCI  for injection. The skin  test  dose ranged  from 0.1  to  1.0 #g in a  vol of 0.1  ml  injected 
intracutaneously on the volar surface of either forearm. 
For vaccination, the lyophilized pep M  preparations were precipitated in aluminum hydrox- 
ide by the method of Chase (21).  All materials except the sodium hydroxide were sterilized by 
membrane filtration and the entire precipitation and packaging procedures were carried out in 
a  sterile room in the Division of Parenteral  Medications under  the direction of Dr.  Kenneth 
Avis at the University of Tennessee College of Pharmacy, Memphis, Tenn.  10 mg of pep M  in 
6 ml of 0.85% NaCI (saline) was mixed with 3.2 ml of a  10% solution of aluminum potassium 
sulfate.  The  solution  was  immediately neutralized  during  thorough  mixing by  the dropwise 
addition of 1.4 ml of 1.0 N  NaOH followed by dropwise addition of 0.4 N  NaOH to reach a 
pH of 6.0.  Sufficient additional saline was then added to make a  total vol of 10 ml. After 1 h, 
the precipitate was centrifuged at  1,000 g for 10 min and resuspended  in 25 ml of sterile saline 
for  a  final  concentration  of 200  ~g  of M  protein  per  0.5  ml  of vaccine  dose.  The  alum- 
precipitated  vaccine was then packaged  in sterile multiple-dose vials and stored at 4°C until 
used. Measurement of the protein content of the first supernate after alum precipitation by the 
method  of Lowry  et  al.  (22)  revealed  that  >95%  of the  pep  M  had  been  adsorbed  to  the 
aluminum gels. 
Both the antigens  used  for skin testing and  the alum-precipitated antigens were tested  for 
sterility,  pyrogenicity,  and  toxicity  according  to  the  protocols  of the  Division of Biological 
Standards of the U. S. Public Health Service (23). All preparations used were within acceptable 
limits. 
Volunteers.  12 healthy male and female volunteers between the ages of 22 and 58 yr (mean 
age, 29 yr) were selected for the human studies. Individuals with histories or evidence of heart 
or kidney disease,  rheumatic  fever, or atopic  allergies were excluded as were those who had 
type-specific antibodies to types 6 or 24 streptococci. All individuals who volunteered for the 
study were informed of the potential  hazards  in compliance with  the standards  of the U.  S. 
Public Health Service, of the Human Use Committee of the University of Tennessee Center for 
the Health Sciences, and of the Memphis Veterans Administration  Hospital. 
All selected individuals were skin tested with 0.1- to  1.0-/tg  doses of pep M  protein injected 
intracutaneously  in  a  total  vol of 0.1  ml  of saline.  Skin-test-negative  individuals  who  were 
chosen for the vaccination studies received the alum-precipitated  type 24 vaccine in doses of 
100-200 p~g of protein injected subcutaneously in the upper lateral aspect of the arm. Sera were 
collected from all vaccinees immediately before the first dose and at  2-wk intervals thereafter 
and  were assayed  for the presence of type-specific, non-type-specific, and  heart  cross-reactive 
antibodies.  Of the  12  volunteers,  2  (G.  S.  and  R. J.)  were  the  subjects  of a  pilot  course  of 
gradually  increasing doses of pep M24  vaccine.  Subsequently,  10 additional  volunteers were 
started on an immunization schedule consisting of three doses of 200 #g of pep M  every 2 wk, 
followed by a fourth 200-/~g dose 3-4 mo after the third dose. Of the 10, 3 received only the first 
two doses because of minor reactions  (Results).  A  fourth  was  unavailable  to receive the last 
dose. Thus, including the two pilot volunteers, eight individuals completed the protocol of four 
doses. 
Type-specific Opsonic Antibody Assays.  In  vitro  timed  phagocytosis  assays  for  type-specific 
opsonic M  antibody were performed as described (14,  16, 24). The assay mixtures consisted of 
0.4  ml  fresh  human  blood  supplemented  with  10  U/ml  of heparin,  0.05  ml  of a  standard 
suspension of streptococci, and 0.05 ml of test serum. The ratio of streptococcal colony-forming 
units (CFU) per leukocyte was -~ 10:1. The percentage of neutrophilic leukocytes that  ingested 
streptococci (percentage of phagocytosis) was estimated by microscopic counts of stained smears 
prepared  from  the  assay  mixture  after  30  min  of incubation.  The  opsonic antibody  titer  is 
expressed as the reciprocal of the highest twofold dilution of test serum that  in three separate 
tests of each serum-produced  phagocytosis of 10%  or greater when  phagocytosis  of the same 
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each  assay.  Type specificity was  demonstrated by  failure of the  immune sera  to  opsonize 
heterologous M serotypes of group A streptococci. 
Bactericidal tests  were performed using the same test  mixtures as described above except 
that a smaller number of streptococci (ranging from 2 to 50 CFU per 0.4 ml of fresh  blood) 
were added to the assay mixtures. The test  mixtures were tumbled end-over-end at 8 rpm at 
37°C for 3 h and finally mixed with melted sheep blood agar to prepare pour-plates for colony 
counts as previously described (7). 
Long-Chain test.  The test was performed according to a method previously described (25). 
Tests for Type-specific Antibody Responses by Enzyme-linked Immunosorbent Assays (ELISA ).  ELISA 
for  anti-M antibodies were performed according to the principles of Engvall and Perlmann 
(26) and as described by Russell et al. (27). 1-ml samples of M  protein antigen dissolved  at a 
concentration of 5 #g/ml in 0.1  M  carbonate buffer, pH 9.6, and supplemented with 0.02% 
NAN3, were incubated for 3 h at 37°C in a series of 12-  ×  75-mm polystyrene tubes (Falcon 
Labware, Div. of Becton, Dickinson, & Co., Oxnard, Calif.). After washing three times with 1 
ml  of 0.15  M  NaC1  containing 0.05%  Tween  20  (saline-Tween; polyoxethylene sorbitan 
monolaurate, Sigma Chemical Co., St.  Louis, Mo.), the antigen-coated tubes were incubated 
with  1-ml samples of immune serum diluted in PBS supplemented with 0.05% Tween and 
0.02% NaN3  (PBS-Tween) for 3 h  at  37°C. After washing again as  above,  1 ml of alkaline 
phosphatase-conjugated rabbit anti-human  IgG (Microbiological Associates, Walkersville, Md.) 
diluted in PBS-Tween was added to each tube and incubated overnight at 37°C. The tubes 
were again washed three times with saline-Tween, after which,  1 ml of a  1 mg/ml solution of 
p-nitrophenylphosphate (Sigma Chemical Co.)  in 0.1 M carbonate buffer, pH 9.6, containing 
1 mM MgClz was added. The enzyme reaction was allowed to proceed for  1 h at 37°C. The 
reaction was stopped  by adding 0.1  ml  1 N  NaOH.  Absorbance was read  at  400  nm in a 
Coleman junior spectrophotometer (Perkin-Elmer, Corp., Instrument Div., Norwalk, Conn.). 
The titer of the test serum was recorded as the inverse of the last serum dilution which gave an 
absorbance of >0.1. 
Assays for Non- Type-specific and Tissue Cross-Reactive Antibodies.  Complement fixation tests were 
performed by a micro technique as previously described (28). The non-type-specific antibody 
titers were expressed  as the reciprocal of the highest dilution of immune serum that inhibited 
lysis of antibody-coated erythrocytes by 50% in the presence of an acid-extracted type 30 M 
protein and complement. 
Immune sera were  tested for the presence of heart cross-reactive antibodies as  previously 
described (18). Frozen sections (4-/tm thick) were prepared from fresh rabbit heart tissue and 
were stored at -80°C. The tissue sections were  incubated with immune serum for 30 rain at 
25°C, washed three times with PBS, treated with fluorescein-labeled goat anti-human IgG (N. 
L. Cappel Laboratories, Cochranville, Pa.) for 30 min at 37°C, again rinsed three times in PBS 
and finally mounted with one drop of glycerol-glycine buffer at pH 7.6 and a glass coverslip. 
The treated sections were examined for  fluorescence with a  Leitz microscope (E. Leitz, Inc., 
Rockleigh, N. J.). 
Analytical Methods.  Protein concentrations in the purified pep M  preparations were deter- 
mined by quantitative amino acid analysis as described (14,  16). Samples were hydrolyzed in 
twice-distilled, constantly boiling HC1 under an atmosphere of nitrogen for 24 h at 108°C. The 
hydrolyzed samples were then analyzed on a  Beckman  121  automatic amino acid analyzer 
(Beckman Instruments, Inc., Fullerton, Calif.) by a single-column technique with a four-buffer 
elution system (20). 
SDS-polyacrylamide gel electrophoresis was performed in 10% gels according to the method 
of Weber and Osborn (19). 
Streptococcal Antisera and Animal Immunization Studies.  Antisera to whole group A streptococci 
were  prepared by immunizing rabbits with heat-killed or ultraviolet-irradiated organisms as 
described (24). The animal immunogenicity  of the purified pep M antigens precipitated with 
alum was studied by injecting mice subcutaneously with  10-/~g doses and rabbits with 50-/~g 
doses  of pep M  at  2-wk  intervals for a  total of three doses.  The rabbits were bled at  2-wk 
intervals and the mice were challenged intraperitoneally 2 wk after the last immunizing dose 
with various doses (ranging from 200 to 2 ×  106 CFU) of homologous or heterologous serotypes 
of group A streptococci suspended in a total vol of 0.5 ml PBS.  The survivals were recorded 866  IMMUNOGENICITY OF M  PROTEIN  IN  MAN 
TABLE I 
Indirect Bactericidal Tests with the Vaccine Strain of the Sera of Rabbits 
Immunized with Alum-precipitated  pep M24 Vaccine 
Number of CFU after 3-h incu- 
bation in test mixture with initial 
Time serum sample collected*  inoculum of: 
9 CFU  3 CFU 
Preimmunization  >2,000  1,280 
2 wk  :>2,000  1,500 
3 wk  1,235  815 
5 wk  340  375 
6 wk  340  125 
8 wk  80  90 
* The sera of two rabbits were pooled for each sample. The indicated times of 
sample collection are the intervals after the first dose of 50 p.g of pep M24. 
Booster doses of 50 #g were given at weeks 2 and 4. CFU, colony forming 
units. 
over a  7-d period. Passive mouse protection tests were performed in the same fashion except 
that instead of vaccination, the mice were injected intraperitoneally with 0.2 ml of immune or 
nonimmune  serum  and  then  challenged by  the same route  24-h  later with  homologous or 
heterologous serotypes of streptococci. The data were analyzed statistically by the method of 
Reed and Muench (29). 
Results 
Structure of pep M  Protein Molecules.  Analysis of each batch of the pep M24 vaccine 
by SDS-polyacrylamide gel electrophoresis, by quantitative amino acid analysis, and 
Edman  degradation confirmed the chemical homogeneity of the pep  M24  antigen. 
The partial amino acid sequences of the M24 molecule were shown elsewhere (16). A 
comparison by computor data analysis of the parts of the molecule already sequenced 
with  >100,000  other proteins whose  amino acid sequences  have  been  reported  (30) 
revealed only minor homologies; the longest matching sequences included a hexapep- 
tide, Glu-Ala-Glu-Lys-Ala-Ala,  a  repeating segment in pep M24, which is shared with 
tropomyosin, a protein of rabbit skeletal muscle. The pentapeptide, Ala-Glu-Lys-Ala- 
Ala which is encompassed in the above hexapeptide is also shared with the hemoglobin 
fl-chains of the rat, the mouse, and the yellow-cheeked vole. 
Aluminum-hydroxide gels have been well-tolerated in man and have been shown 
to  serve  as  good  adjuvants  for  the  stimulation  of the  immune  responses  to  other 
vaccine antigens (21). Therefore, the pep M24 antigen was incorporated into alumi- 
num  gels for the following studies. 
Immunogenicity of Alum Precipitates of pep M24 in Rabbits.  In vitro phagocytosis tests 
of sera obtained from  two rabbits immunized twice a  week with  50-/zg doses of pep 
M24  in alum  indicated that  both animals developed peak levels of type 24 opsonic 
antibodies 6 wk after the initial immunizing dose. Indirect bactericidal tests for M24 
antibodies  confirmed  these  results.  The  number  of viable streptococci  capable  of 
surviving  incubation  in  rotated  test  mixtures  containing  fresh  human  blood,  the 
vaccine  strain  in  type  24  streptococci,  and  rabbit  immune  serum  decreased  with 
increasing time intervals after the first immunizing dose (Table I). 
Assays of the  antisera  in  immunofluorescence  tests made  with  frozen  sections of BEACHEY,  STOLLERMAN,  JOHNSON,  OFEK,  AND  BISNO  867 
TABLE  II 
Type-specific Protective Immunogenicity of Alum Precipitates of pep M24 in 
Mice Challenged with Type 6 or Type 24 Streptococci 
Mice immunized with: 
LDso in mice challenged with:* 
Type 6 strepto-  Type 24 strepto- 
cocci  cocci 
PBS-alum (control)  <200  <200 
pep M24-alum  <200  >2,000,000 
* The mice were immunized and challenged with streptococci as described in 
the text. The number of deaths was recorded over a  period of 7 d. 
human heart tissue confirmed that heart cross-reactive antibodies were absent. These 
results are consistent with previous studies indicating that sera from animals hyper- 
immunized with  pep M24  in  complete Freund's  adjuvant  were free of heart  cross- 
reactive antibodies (18). 
Protective Immunogenicity  of Alumoprecipitated pep M24 in mice.  To assess more directly 
the protective properties of the pep M24 vaccine, 30 mice were immunized twice a 
week with  10-/~g doses subcutaneously of pep M24 precipitated  in alum.  30 control 
mice were injected in the same way with alum alone. 2 wk after the last injection,  15 
mice in each group were challenged with the vaccine strain of type 24 streptococci, 
and the remaining  15 in each group were challenged with a  heterologous serotype 6 
strain of streptococci. The animals were further divided into subgroups of three mice 
and injected intraperitoneally with various doses of streptococci ranging from 200 to 
2,000,000  CFU  in  a  total  vol of 0.5  ml.  None of the  unimmunized  mice survived 
challenge infections with as few as 200 CFU of either serotype of streptococcus (Table 
II), nor were there any survivors among the pep M24-immunized  mice challenged 
with  type 6  streptococci.  In contrast,  all  but  one of the  pep M24-immunized  mice 
survived  challenge  infections  of the  homologous vaccine strain  in  doses  as  high  as 
2,000,000 CFU. 
These  results  indicated  that  the  pep  M24  molecule  precipitated  in  aluminum 
hydroxide was immunogenic, and evoked type-specific protective immunity in labo- 
ratory  animals.  Together  with  the  knowledge  that  the  pep  M24  molecule  was 
structurally  unique  and  did  not  induce  non-type-specific  (14,  15)  nor  heart  cross- 
reactive antibodies,  these results encouraged  us to pursue pilot studies  of its immu- 
nogenicity in man. 
Human Skin tests and Determination  of pep M24  Vaccine Dose.  Skin tests of all 37 adult 
volunteers  tested  with  1-/lg  intradermal  doses  of  pep  M24  were  negative,  and 
intradermal  doses as high as 40 #g were well-tolerated. This contrasted with almost 
universally positive skin reactions ranging from immediate, to delayed-type reactions 
to 1-/~g doses of M  protein vaccines prepared from conventional HCI extracts of group 
A streptococci (31). 
2 of the 37 adult volunteers were chosen to determine the dose of alum-precipitated 
M  antigen required to induce a type-specific opsonic antibody response. Initially, 100- 
/~g doses were administered subcutaneously at ~ 1-mon intervals. Opsonic antibodies, 
however,  did  not  become detectable  even  after  three  such  doses.  The  dose  of M 
protein, therefore, was increased to 200 #g and given at 2-wk intervals. A brisk opsonic 
antibody response was observed 2 wk after the first  200-#g dose, reaching a  titer of 868  IMMUNOGENICITY OF M PROTEIN IN MAN 
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FIG.  1.  Opsonic antibody response of one of the human volunteers used to determine the dose of 
pep  M24  vaccine  needed  to  produce  a  primary  immune  response.  The  doses  and  intervals  of 
injection of the alum-precipitated pep M24 are indicated by the arrows. 
1:16  (Fig.  1).  Opsonic antibody was still  present  at  a  titer of 1:4  14 wk later,  and a 
reinforcing dose of 200 #g boosted the  antibody titer  to  1:16.  Neither of these  two 
vaccinees  had  any  complaints  except  for  mild  local  irritation  after  receiving  the 
subcutaneous injections of vaccine. 
Type-specific  Opsonic Antibody  Responses  in  Human  Volunteers.  Based  on  the  above 
results,  another ten of the skin test-negative volunteers were immunized with 200-/~g 
doses of alum-precipitated M  protein at 2-wk intervals. The response of one of these 
vaccinees is depicted in Fig. 2. Low levels  of type 24 opsonic antibody appeared at 4 
wk and reached a peak titer of 1:32 at 8 wk, similar to the response seen previously in 
rabbits  (above).  No opsonic antibodies were formed against the heterologous type 6 
streptococci during the course of immunization with pep M24. 
8 of the  10  vaccinees developed opsonic antibodies 6 wk after the  initial  dose of 
vaccine (Table III). The number showing detectable opsonic antibodies fell to 3 of 10 
at  10 wk. 
Of the  total  of 12  volunteers,  9  had  no significant  local or systemic reactions  to 
injections of the pep M24-alum vaccine. Of the remaining three, one had a  transient 
low-grade fever (38°C)  after the second dose, one had transient  (224 h)  local indur- 
ation,  and  one  had  a  transient  mild  exacerbation  of a  chronic  rash.  These  three 
volunteers  did  not  receive  a  third  dose.  These  results  indicated  that  the  pep  M24- 
alum  vaccine  was  well-tolerated  in  sufficient  doses  to  produce  a  primary  opsonic 
antibody response. 
Development  of  Type-specific  Delayed  Cutaneous Hypersensitivity  in  pep  M24  Vaccinees. 
Skin tests of the immunized individuals showed that  10 of the 12 converted to positive 
delayed-type reactions  (maximum responses  at  24 h)  to the homologous type 24 M 
protein  (Table IV). Only four converted to positive reactions when skin tested with 
type 6 M  protein. These results indicate that the production of hypersensitivity was BEACHEY,  STOLLERMAN, JOHNSON,  OFEK, AND  BISNO  869 
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Ftc.  2.  Type-specific opsonic antibody response in a human volunteer injected with three 200-#g 
doses of pep M24 in alum at 2-wk intervals (arrows). (0) type 24 streptococci, (0) type 6 streptococci. 
TABLE  III 
Immunogenicity of  pep M24 in Humans as Determined  by Opsonic Antibody 
Responses 
Opsonic antibodies~ (No. posi- 
Dose of pep M24"  Time  tive/No, tested§) 
#g  wk 
200  0  0/10 
200  2  ND 
200z~  4  1/10 
--  6  8/10 
--  8  8/lO 
--  10  3/10 
ND, not done. 
§ Data on first two pilot volunteers not included in this table (text and Fig. 2). 
* M protein was injected intramuscularly as an alum precipitate in a total vol 
of 0.5 ml (Materials and Methods). 3 of the 10 volunteers did not receive a 
third dose (text). 
:1: Opsonic  antibodies against  type  24  streptococci were  assayed  in  timed 
phagocytosis  tests as described in Materials and Methods. A positive  test is 
defined as one in which phagocytosis after 30 min at 37°C is 10% or greater 
when phagocytosis  of the same organisms in  the presence of preimmune 
serum from the same individual is equal to one-half  or less than that of the 
test serum. 
mostly type specific but  also suggested that  types 6  M  and  24  M  protein molecules 
may  share  certain  minor  determinants.  One  individual  who  had  measurable  M24 
antibodies in  his  serum  before immunization  and  was  therefore excluded from the 
study showed positive delayed-type skin reactions to pep M24. 870  IMMUNOGENICITY OF M  PROTEIN  IN MAN 
TABLE  IV 
Development of Type-specific Delayed-Type Skin Reactions in Human 
Volunteers Immunized with pep M24 Vaccine 
Skin reactions:~ (No. positive/No, tested) 
Skin test antigen* 
preimmunization  postimmunization 
pep M24  0/12  11/12 
pep M6  0/12  4/12 
* The purified antigens (1.0 ~g) were injected in a total vol of 0.1 ml of sterile 
saline.  Control sites were injected with the same volume of saline without 
antigen. 
Skin tests were performed before immunization and 4-10 wk after the initial 
vaccine dose. The numbers represent  accumulated positive reactions  over the 
accumulated number of individuals tested.  A positive reaction is defined as 
induration of 10 mm in Diam or greater, 24 h after the intradermal injection. 
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FiG.  3.  Type-specific immune  response  to  injections  of alum-precipitated  pep  M24  in  normal 
human volunteers as measured by ELISA. The vertical bars indicate the mean and one SD from the 
mean of the preimmune and  postimmune values obtained using pep M24  (A) or pep M6 (B)  as 
antigen. 
ELISA of the Antibody Response to the pep M24 Vaccine in Man.  To determine the total 
humoral antibody response to immunizing  doses of the M24 molecule, the preimmune 
and  postimmune  sera  of the  human  vaccinees  were  assayed  by  a  sensitive  ELISA 
method  using either the homologous  pep  M24 or the heterologous  type 6  M  protein 
peptic  extract  (pep  M6)  as  antigens.  The  total  humoral  antibody  responses  were 
almost  entirely specific for the pep  M24  vaccine  (Fig.  3).  Only one vaccinee showed 
an antibody rise of more than two tubes against the pep M6 molecule, whereas all the 
vaccinees developed significant antibody  rises against  the pep M24  molecule. 
Development  of Type-specific  Bactericidal  and  Mouse  Protective Antibodies  in  the  Sera of 
Vaccinees.  To  demonstrate  that  the  immune  sera  of the human  vaccinees contained 
protective antibodies  against  the vaccine strain of type 24 streptococci, we performed 
indirect bactericidal  and  mouse protection  tests.  By the indirect bactericidal  test, five 
of eight  immune  sera  tested  from  the  vaccinees  inhibited  the  growth  of  type  24 BEACHEY,  STOLLERMAN, JOHNSON,  OFEK,  AND  BISNO  871 
TABLE V 
Inhibition of Growth of Type 24 Streptococci in Fresh, Normal Human Blood 
in the Presence  of the Sera of  pep M24  Vaccinees * 
Vaccinees 
No. of CFU in presence  of sera:~: 
preimmune  immune 
D.L.  >1,500  61 
R.F.  >1,500  6 
S.G.  >1,500  0 
B.M.  >1,500  >1,500 
H.C.  >1,500  >1,500 
S.C.  >I,500  >1,500 
G.S.  > 1,500  0 
R.J.  >1,500  0 
Rabbit (pooled serum) §  > 1,500  90 
* Includes the eight volunteers who completed the full course of immunization 
(four doses, each of 200 #g). 
:~ The test mixtures consisted  of 0.4 ml fresh, nonimmune human blood, 0.05 
ml human or rabbit serum, and 0.05 ml of a suspension  of ~ 10 CFU of type 
24 streptococci.  The mixtures were incubated at 37°C by rotation at 8 rpm 
for  3  h.  The  surviving CFU  were  determined  by  preparing  pour-plate 
cultures from the test mixtures. 
§ Pool of two sera  obtained from rabbits immunized with alum-precipitated 
pep M24 (see Table I). 
TABLE VI 
Long-Chain Formation of M24 Streptococci in the Presence  of Vaccinee's Sera * 
Vaccinees 
Mean No. of streptococci  in chain  ±  SEM 
Preimmune  Postimmune 
D.L.  6.6  +  0.5  23.5  +  1.1 
R.F.  7.7  ±  0.6  32.6  +  1.4 
S.G.  6.2  ±  0.5  30.6  +  2.0 
B.M.  7.6 ±  0.7  9.1  +  0.6 
H.C.  8.0  +  0.7  12.7 +  1.1 
S.C.  10.2 +_ 0.8  13.8:1:1.4 
G.S.  7.1  ±  0.5  57.1  __. 4.7 
R.J.  6.7  ±  0.6  32.5  +  2.6 
* Sera tested were the same as those studied by the bactericidal test (Table V). 
streptococci in flesh human  blood (Table V). In control experiments  (data not shown) 
the  growth  of type  6  streptococci  was  not  inhibited  in  the  presence  of the  immune 
sera in the fresh  blood test  mixtures.  Uninhibited  growth of both  type 24 and  type 6 
streptococci  in  plasma  and  immune  sera  alone confirmed  that  inhibition  of growth 
required the presence of phagocytic cells. The same sera were also tested by the long- 
chain  test  (25)  for  type-specific  anti-M  antibody.  All  sera  positive  for  bactericidal 
antibodies  produced  strongly  positive  type-specific  long-chain  reactions  (Table  VI). 
For  tests  of the  protective  effect of the  human  M24  antisera,  mice were  injected 
intraperitoneally  with  0.2  ml  of human  preimmune  or  immune  sera.  1  d  later,  the 
mice were  challenged  by  the  same  route  with  various  doses  of homologous  type  24 
streptococci  or heterologous  type 6  streptococci.  Of the  12  mice that  received preim- 
mune serum and then were challenged with type 24 streptococci,  11  died (Table VII). 872  IMMUNOGENICITY OF M  PROTEIN IN MAN 
TABLE  VII 
Mouse Protection by Sera of Vaccinees Immunized with pep M24-Alum 
No. deaths/No, challenged with:  Mice injected with human 
serum from:  Type 6 strep  Type 24 strep 
Unimmunized  7/12  11 / 12 
Vaccinee No. 1  6/12  1/12 
Vaccinee No. 2  7/12  1/12 
TABLE VIII 
Non-Type-specific Immune Response to Injectwns of  pep M24 in Normal 
Human Volunteers as Measured by CF Test with Crude M30 Antigens * 
Vaccinees  Preimmune (serum titer)  Postimmune (serum titer) 
D.L.  l:10  <1:10 
R.F.  <1:10  <1:10 
S.G.  1:20  1:20 
B.M.  <I:10  <1:10 
H.C.  <1:10  <1:10 
S.C.  l:40  1:80 
G.S.  1:20  1:20 
R.J.  1:10  <1:10 
In contrast, only one of each of the groups of 12 mice injected with human immune 
sera succumbed to type 24 infections. This compared to six or seven deaths in each of 
the groups of 12 mice injected with preimmune or immune sera and then challenged 
with type 6 streptococci. These results  indicated  that vaccination with the pep M24 
vaccine induced the formation of type-specific bactericidal,  long-chain forming, and 
protective antibodies in man. 
Lack of Cross-Reactivity  of the Vaccinees" Sera with Non-Type-specific M-associated Antigens 
or with  Human  Heart  Tissue.  To  determine  whether  or  not  the  vaccinated  subjects 
developed antibody rises to the non-type-specific, M-associated antigens (14), the sera 
were tested by a  microcomplement-fixation  test,  using an acid-extracted  type 30 M 
protein as antigen.  Previous studies  (14, 28) have shown that the M30 preparation  is 
rich  in  antigenic  determinants  common  to  M  protein  preparations  from strains  of 
many M  types.  None of the  12  pep  M24  vaccinees  developed  significant  antibody 
titer rises  to the type 30 preparation  (Table VIII). Finally, heart-reactive  antibodies 
were not detected  in immune sera of any of the twelve vaccinees by immunofluores- 
cence techniques. 
Discussion 
In this  investigation,  the  immune response to pep  M24 was measured  by a  wide 
variety of assays which are designed to detect  respectively  (a)  type-specific humoral 
antibodies  (opsonocytophagic, long chain, and mouse protection);  (b)  total humoral 
antibodies  (complement  fixation  [CF]  and  ELISA);  (c)  cellular  immunity  (delayed 
skin test); and (d)  heart tissue cross-reactive antibodies  (immunofluorescence).  From 
these studies,  it appears that  type-specific primary immune responses in man to the 
alum-precipitated  pep M24 antigen can be stimulated in most individuals with doses 
that are well-tolerated  and that are within conventionally acceptable limits for other BEACHEY, STOLLERMAN, JOHNSON,  OFEK, AND BISNO  873 
vaccines in common use. This result  is gratifying, if not surprising, considering past 
experience with  immunization  in  man with other partially-purified preparations of 
M  protein  (1).  Lancefield's early studies  (32)  in animals comparing the antigenicity 
of acid-extracted M  protein with that of whole heat-killed streptococci suggested that 
purification  of  the  M  antigen  was  associated  with  diminished  immunogenicity. 
Indeed, the M  antigen was first suspected as being haptenic until its antigenicity was 
confirmed  by its administration  to animals  in  larger doses  (33).  Most  investigators 
have been disappointed with their inability to achieve a  high percentage of primary 
immune responses  in  man with  the  doses of vaccine to which  their regimens were 
confined  (34-41).  For example,  Schmidt  (34)  was  only able  to  achieve a  primary 
immune response in  2  of 24 children  who received a  total dose of 300 gg of alum- 
precipitated type 19 acid-extracted M  protein. In studies by Fox and associates (41), 
acid-extracted  and  alum-precipitated  preparations were injected  in  relatively small 
doses  (90 gg per dose  for three  monthly  doses)  in  19  adults,  5  of which  developed 
opsonic antibody. Because of these reports and our own previous experience (31), we 
expected that limited peptic digestion and purification of the M  protein to the extent 
of producing  a  structurally  defined  molecule containing  the  M  determinant  might 
indeed  have  resulted  in  a  further  loss  of  immunogenicity.  Our  findings  provide 
evidence for a  stronger and more consistent  immune response than  we anticipated. 
Perhaps the reason for the relatively high frequency of our primary responses to pep 
M24  is  the  high  concentration  of specific  determinant  per  weight  in  our  pep  M 
preparation. 
The human adult host is naturally hyperimmune to a wide variety of streptococcal 
protein antigens and most human sera contain antibodies reactive with common non- 
type-specific M  (NTSM)  determinants that have not been removable from previous 
M protein preparations (7-11). Immunization with M protein preparations containing 
even small amounts of NTSM should,  therefore,  readily boost such antibody titers. 
Previous studies have, in fact, shown that pharyngeal infections with group A strains 
of virulent M  types, and particularly those producing rheumatic fever, are associated 
with  high  titers  of complement-fixing antibodies  to NTSM  (8,  27).  The M  protein 
vaccines used by Fox and associates (41) regularly produced increased levels of passive 
hemagglutinating antibodies to M proteins, but these antibodies were not type-specific 
and were therefore probably directed against NTSM. The homogeneity of the immune 
response to the type-specific determinant  in  the pep M24  vaccinees is suggested by 
the absence of increases in complement-fixing antibodies  to NTSM  in any of these 
individuals.  That  only  1 of the  12  individuals  immunized with  pep M24 showed  a 
significant increase in antibodies directed against pep M6 in the ELISA supports this 
interpretation.  Further studies of the applicability of the ELISA to the measurement 
of the  type-specific determinants  of M  proteins  prepared  by the  pepsin-extraction 
method  are  in  progress.  2 If this  test  can  be employed with  pep  M  preparations  to 
measure,  reliably  and  exclusively,  type-specific  M  determinants,  the  problems  of 
measuring type-specific antibodies by biological tests dependent upon live cultures of 
virulent streptococci and special donor serum characteristics may be obviated. 
The  results  of  the  skin  test,  perhaps  the  most  sensitive  indicator  of antigenic 
2 Dale, J., I. Ofek, and E. H. Beachey. Enzyme-linked  immunosorbent  assay (ELISA)  of the type specific 
immune response in humans vaccinated with streptococcal M protein. Manuscript submitted for publica- 
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homogeneity, also support the type-specificity  of the immune response of the vaccinees. 
11 of 12 vaccinees developed delayed cutaneous hypersensitivity (DCH) to pep M24 
which were mostly of the Jones-Mote type (42).  4 of the  12 vaccinees did, however 
develop cross-reacting skin tests to pep M6.  Alternatively, both preparations  might 
have been contaminated with minute amounts of NTSM that were not detected by 
any of the other methods for measuring humoral immunity that  we employed. On 
the whole, however, these skin tests represent the most convincing demonstration of 
type-specific DCH to M  protein preparations of which we are aware. 
A preliminary study of the pep M24 molecule for homologies with other proteins 
of known amino acid sequences has been undertaken using a computer search (30). 
The antigen appears to be unique and related only distantly to other proteins recorded 
in  the  program.  Whether or not  homologies between  pep  M  proteins  of different 
serotypes will  be revealed by similar analysis must  await  further sequencing of the 
amino acids in such preparations. 3 A comparison of pep M24 and pep M6 by these 
methods is in progress (J. Seyer and E. H. Beachey. Manuscript in preparation.). 
The studies reported here may move us closer to the capability of immunizing man 
against infection with specific M  types of group A streptococci. There is, thus far, no 
evidence that  antibodies to the type-specific M  determinant itself are related to the 
pathogenesis of rheumatic fever. A  polyvalent vaccine to structurally defined type- 
specific M  determinants  with  or without  appropriate  adjuvants  may be  useful  in 
certain targeted populations. A recent review of the literature reveals that the number 
of streptococcal M  types that  have been clearly associated with rheumatic  fever in 
reports of well-defined outbreaks of group A streptococcal pharyngitis is surprisingly 
few, perhaps a  dozen or less  (43).  Certain types such as M5 have been particularly 
frequently associated with rheumatic fever. The so-called skin types causing strepto- 
coccal pyoderma do not appear to cause rheumatic fever (44).  A polyvalent vaccine 
against  rheumatic fever might, therefore, be confined to a  relevant pool of M  types 
found in selected populations.  Moreover, a  certain targeted population at high risk 
for rheumatic recurrences, such  as young individuals  with  rheumatic heart  disease 
(45), might benefit by protection against  known rheumatogenic M  types  (46). The 
absence of any trace of heart-reactive antigens in our preparations and  the relative 
antigenic homogeneity of our preparations may encourage eventual vaccine trials in 
such selected populations. 
Summary 
We tested the ability of pepsin-extracted, highly purified M  protein to induce type- 
specific immunity  in  experimental animals  and  humans.  M  protein  was  prepared 
from limited peptic digests of whole group A type 24 streptococci and was purified to 
chemical homogeneity as judged by sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis, quantitative amino acid analysis, and Edman degradation. For vaccina- 
tion, the lyophilized M24 protein preparation (pep M24) was precipitated in alumi- 
num hydroxide. When injected into laboratory animals, alum-precipitated pep M24 
produced type-specific protective antibodies and was free of non-type-specific immu- 
a A comparison of the amino terminal segments of pep M24 and a similarly purified polypeptide of type 
5 M  protein (pep M5) has revealed identical amino acid residues at positions 3,  15,  18, 2l, 23, 24, and 27 
(J. E. Seyer and E. H. Beachey. Manuscript in preparation.). The significance of these homologies with 
respect to cross-reactive and protective immunity is now being further investigated. BEACHEY, STOLLERMAN,  JOHNSON, OFEK,  AND BISNO  875 
noreactivity.  In man,  skin  tests with  1-#g doses of pep M24 were negative  in all  37 
adults  tested.  12 adult  human  volunteers received two-four subcutaneous  injections 
of 100-200 #g of alum-precipitated pep M24 at intervals of at least 2 wk. The immune 
response to pep M24 was measured by a variety of assays designed to detect  (a) type- 
specific  humoral  antibodies  (opsonophagocytic,  long  chain,  and  mouse  protection 
tests);  (b)  total humoral  antibodies  (complement  fixation and enzyme-linked immu- 
nosorbent  assay);  (c)  cellular  immunity  (skin  tests);  and  (d)  heart  cross-reactive 
antibodies (immunofluorescence). Type-specific opsonic antibodies developed in 10 of 
the  12 vaccinees,  and positive delayed-type skin tests developed in  11.  Immune sera 
from two of the vaccinees were effective in mouse-protection  tests  against  challenge 
with M24 but not M6 streptococci. None of the volunteers developed heart-reactive 
antibodies  or antibodies  to non-type-specific M  protein  antigens.  Alum-precipitated 
pep M24 was well-tolerated  in man, and no serious local or systemic reactions were 
observed. Thus, pep M24 induces type-specific, protective antibodies in doses that are 
well-tolerated  in man. 
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performing the ELISA, Dr. Michael Alkan, who participated in the early part of these studies, 
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